Esperion Therapeutics | ESPR - Debt

Stock Price
3.49
Daily Change
0.10 2.80%
Monthly
-1.83%
Yearly
85.37%
Q1 Forecast
2.70

Esperion Therapeutics reported $262.92M in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Alterity Therapeutics Limited AUD 210.39K 120.67K Jun/2023
Amarin USD 0 0 Mar/2025
Amgen USD 54.59B 1.62B Sep/2025
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Cipla INR 4.38B 231.9M Mar/2025
CSL USD 11.96B 219M Dec/2024
Cytokinetics USD 858.06M 199.93M Jun/2025
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Geron USD 121.84M 3.12M Jun/2025
Grifols EUR 9.23B 626.05M Dec/2024
Halozyme Therapeutics USD 1.51B 1.65M Jun/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 741M 4M Jun/2025
Nektar Therapeutics USD 0 0 Jun/2022
Pfizer USD 60.85B 78M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Sanofi EUR 21.76B 530M Sep/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
United Therapeutics USD 200M 100M Mar/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024